NV-ROBOSENSE
8.1.2020 15:02:09 CET | Business Wire | Press release
RoboSense (http://www.robosense.ai ), the leading autonomous driving LiDAR perception solution provider, announced today the world’s first public road test of a vehicle equipped with a Smart LiDAR Sensor at CES 2020 . The RoboSense Smart LiDAR car, featuring the award-winning RS-LiDAR-M1 Smart LiDAR , will be running outside the Las Vegas Convention Center daily during CES 2020, showing the latest technological progress in autonomous vehicle LiDAR. Simultaneous exhibitions will be held at RoboSense’s CES Booth #6138 at the LVCC, North Hall showcasing the real-time 3D point cloud data on a vehicle equipped with the multi solid state LiDAR fusion system.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200108005303/en/
First MEMS Smart LiDAR Sensor to Incorporate Sensor Hardware, AI Perception Algorithms, & IC Chipsets
The RoboSense RS-LiDAR-M1 Smart LiDAR is the world’s first MEMS Smart LiDAR Sensor to incorporate sensor hardware, AI perception algorithms, and IC chipsets, transforming conventional LiDAR sensors from an information collector to a complete data analysis and comprehension system, providing essential information for autonomous vehicle decision-making faster than ever before. The RS-LiDAR-M1 is the winner of the CES Innovation Award for two consecutive years in a row, 2019 and 2020.
RoboSense Co-Partner and Vice President of R&D, Dr. Leilei Shinohara, said, “After optimization based on large amounts of data, RoboSense’s algorithm performance and software stability and reliability have proven to have many key advantages. Developed by RoboSense after more than a decade of exhaustive research in perception technology, it has combined the advantages of deep-learning-based AI algorithm with the traditional algorithms to keep functional safety. Since 2017, RoboSense’s algorithms have gained more than 100 global partners for various types of autonomous driving scenario certifications.”
At CES and on the streets of Las Vegas, the RoboSense RS-LiDAR-M1 Smart is demonstrating that it is the world’s first and only Smart LiDAR capable of real road tests on open roads .
128 Laser Beam System & Fastest Mass-produced Short-range LiDAR for Blind Spot Detection
During CES 2020, RoboSense128-beams LiDAR RS-Ruby and the short-range Blind Spot LiDAR RS-BPearl also go on public road demo, meanwhile there is also a simultaneous exhibition at RoboSense Booth. This super high-performance 128-beam LiDAR RS-Ruby possesses an ultra-high resolution of 0.1° and the range performance of 200m for a 10% reflectivity target.
The RS-BPearl, the first mass-produced short-range LiDAR for blind-spot detection, reaches the minimum detection range of less than several centimeters, with hemispheric FOV coverage of 90° * 360°, which not only precisely identifies objects around the vehicle’s body, but can also detect the actual height information in particular scenarios, such as with bridge tunnels and culverts.
RoboSense Partner Demonstrations at CES 2020
RoboSense has partnerships with numerous industry leaders who will be announcing partnerships or co-demonstrating with RoboSense at CES, including ON Semiconductor, Xilinx, Horizon, AutoX, and Freetech.
Wade Appelman, Vice President of ISG, SensL Division, ON Semiconductor, said, “The combo of RoboSense LiDAR with the ON Semiconductor RD Series SiPM family of products will perform much better than the older APD technology employed by legacy LiDAR manufacturers using mechanical scanning architectures, further enhancing the performance of the RS-LiDAR-M1 to be one of the best in the automotive LiDAR market.”
About RoboSense
The world’s leading autonomous driving LiDAR perception solution provider. http://www.robosense.ai .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200108005303/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom